Overview
OTLK market data
Price History
OTLK price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.79 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.77 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.16 – $3.39 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $247.8 · P/B 31.58 · P/S 583.09.
Company news
Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMDGlobenewswire Inc · Jul 24, 2026, 7:15 PM
Trading Halt: Halt status updated at 2:55:00 PM ET: Quotation Resumption: News and Resumption TimesBenzinga · Jul 24, 2026, 6:55 PM
Outlook Therapeutics Says FDA Approves LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration, Commonly Known As Wet AMDBenzinga · Jul 24, 2026, 6:41 PM
Trading Halt: Halted at 1:34:30 p.m. ET - Trading Halt: Halt News PendingBenzinga · Jul 24, 2026, 5:34 PM
8-K filing — Outlook Therapeutics, Inc. (OTLK)SEC EDGAR · Jul 23, 2026, 11:54 PM
Outlook Therapeutics Files Prospectus For Offering 17.258M Common Shares On Behalf Of Selling StockholdersBenzinga · Jul 17, 2026, 8:10 PM
Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth TimeBenzinga · Jun 17, 2026, 12:45 PM
Outlook Therapeutics Says FDA Accepts Resubmitted BLA For ONS-5010/LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration; PDUFA Target Action Date July 29Benzinga · Jun 16, 2026, 12:15 PM
Outlook Therapeutics shares are trading higher after Ascendiant Capital raised its price target on the stock from $6 to $10.Benzinga · Jun 11, 2026, 5:31 PM
Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For ThursdayBenzinga · Jun 11, 2026, 11:49 AM